RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 COAG Trial: No Advantage Seen with Genetic-Based Warfarin Dosing
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 20
SP 22
OP 22
DO 10.1177/155989771320010
UL http://mdc.sagepub.com/content/13/20/22.1.abstract
AB Warfarin is a widely used medication with a very narrow therapeutic window. Limited evidence suggests that utilizing pharmacogenetic information on top of clinical information could improve warfarin dosing, but large, well-conducted studies are lacking. This article discusses the key results of the Clarification of Optimal Anticoagulation Through Genetics trial [COAG; Kimmel SE et al. N Engl J Med 2013], which compared warfarin initiation using a clinical algorithm with or without the addition of pharmacogenetic information.